C12N 2770/30011
Nodaviridae
C12N2770/30011 (Nodaviridae) appears on 23 US grants and 40 published applications in this corpus.
Search patents in C12N- Granted patents
- 23
- Published applications
- 40
- Assignees
- 31
- Inventors
- 97
- Latest grant
- 16 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 3 |
| 2003 | 1 | 3 |
| 2004 | 2 | 2 |
| 2005 | 0 | 2 |
| 2006 | 0 | 2 |
| 2007 | 1 | 1 |
| 2008 | 0 | 2 |
| 2009 | 0 | 2 |
| 2010 | 1 | 0 |
| 2011 | 1 | 0 |
| 2012 | 1 | 2 |
| 2013 | 1 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 2 |
| 2016 | 1 | 4 |
| 2017 | 1 | 2 |
| 2018 | 2 | 2 |
| 2019 | 3 | 3 |
| 2020 | 2 | 3 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/30022New viral proteins or individual genes, new structural or functional aspects ofIndexing code11
- C12N 2770/30034Use of virus or viral component as vaccineIndexing code8
- C12N 2770/30023Virus like particles [vlp]Indexing code4
- C12N 2770/30051Methods of production or purification of viral materialIndexing code4
- C12N 2770/30041Use of virus, viral particle or viral elements as a vectorIndexing code3
- C12N 2770/30061Methods of inactivation or attenuationIndexing code2
- C12N 2770/30021Viruses as suchIndexing code1
- C12N 2770/30032Use of virus as therapeutic agent, other than vaccineIndexing code1
Recent patents
- Engineering virus-like nanocarriers for biomolecule delivery16 Sep 2025US 12,415,837 B2University of Utah Research Foundation
- Virus-free cell lines and methods for obtaining same18 Oct 2022US 11,473,055 B2Glycobac, LLC
- DNA constructs for manufacturing bio-therapuetic polypeptides for use in animal vaccines and therapeutics24 Nov 2020US 10,844,382 B2MicroSynbiotiX, Ltd.
- Feed additive composition for immunoprotection of fish against infectious viral species6 Oct 2020US 10,792,354 B2Allotropic Tech, LLC
- Algal based edible vaccines19 Nov 2019US 10,480,002 B2Transalgae Israel Ltd.
- Self-amplifying non-coding rna for targeted gene knockdown13 Aug 2026US 2026/0234618 A1The Regents of the University of California
- Synthetic mrna lacking a polya tail or having a short adenine homopolymer and methods of use and production thereof6 Aug 2026US 2026/0226462 A1Elixirgen Therapeutics, Inc.
- Engineered nodaviral cargo delivery systems26 Sep 2024US 2024/0318202 A1Arizona Board of Regents on Behalf of the University of Arizona
- Virus-free cell lines and methods for obtaining same23 Feb 2023US 2023/0059552 A1Glycobac, LLC
- Non-cross-linked acellular pertussis antigens for use in combination vaccines7 May 2020US 2020/0138927 A1Glaxosmithkline Biologicals SA
Most cited
By later US patents
- Recombinant nodavirus compositions and methods19US 6,171,591 B2Pentamer Pharmaceuticals, Inc. · 2001
- Plant expression vectors based on the flock house virus genome6US 6,700,038 B1Wisconsin Alumni Research Foundation · 2004
- Molecular presenting system4US 5,932,426 AInternational Centre For Genetic Engineering and Biotechnology Trieste · 1999
- Norovirus infected cell cultures and uses therefor2US 7,264,923 B2Washington University · 2007
- Antitoxin and vaccine platform based on nodavirus VLPs2US 7,998,487 B2The Salk Institute for Biological Studies · 2011